More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Incyte hopes to sneak Zynyz through the back door
In first-line NSCLC the drug beats chemo, and not Keytruda.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
